Pharma firm Aurobindo Pharma on Friday said it has received final approval for from US health regulator for Lamotrigine tablets used to treat epilepsy.
The company has received final approval from US Food and Drug Administration (USFDA) for Lamotrigine tablets (chewable, dispersible), Aurobindo Pharma said in a filing to the Bombay Stock Exchange.
The tablets are in strengths of 5 mg and 25 mg, the filing added.
Lamotrigine tablets falls under the central nervous system segment and the product would be launched soon, it said.
Aurobindo now has a total of 107 Abbreviated New Drug Application (ANDA) approvals (78 final approvals and 29 tentative approvals) from USFDA.
